Taiwanese drug developer Senhwa Biosciences said Sunday that its investigational drug for the treatment of severe COVID-19 infections has received positive reviews from an independent monitoring group in the United States, and its clinical trials can go forward.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
U.S. dollar up in Taipei trading
04/19/2024 10:24 AM - Business
Taiwan shares open lower
04/19/2024 09:09 AM - Politics
MOFA warns against trusting documents sold on dark web
04/18/2024 10:05 PM - Politics
Taiwan eyes 50% female representation in parliament: VP-elect
04/18/2024 09:51 PM - Politics
Taiwan upgrades satellite network system on Taiping Island
04/18/2024 09:22 PM